首页> 美国卫生研究院文献>Oncotarget >Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas
【2h】

Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas

机译:长期的非编码RNA表达谱的分析确定了胶质瘤的发生和恶性进展中的新型lncRNA生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Long non-coding RNAs have been shown to be associated with cancer development and progression, demonstrating potential applications as novel diagnostic or prognostic molecular markers in clinical management and treatment. However, the functional significance of lncRNAs in the development and malignant progression of gliomas is still unclear and needed to be further explored. we first obtained genome-wide lncRNA expression profiles in a large cohort of patients with gliomas from the Gene Expression Omnibus database using microarray probes repurposing method and investigated the lncRNA expression patterns during the tumorigenesis and malignant progression of gliomas. By using differential expression analysis, we identified a large number of lncRNAs that were associated with the tumorigenesis and malignant progression of gliomas in the training dataset and showed their robustness in the testing dataset. Subsequently, we identified a novel four-lncRNA signature which was closely related to the prognosis of patients with GBM. The prognostic value of this signature was verified in the test set of 80 patients. Functional analysis suggested that the four lncRNAs associated with survival of patients with GBM may be involved in cancer-related biological processes and pathways and their deregulation may lead to GBM tumorigenesis and progression. These novel lncRNA biomarkers will improve our understanding of the molecular mechanisms during the development and progression of glioma and provide novel diagnostic or prognostic markers and therapeutic targets for gliomas.
机译:长期的非编码RNA已被证明与癌症的发展和进展有关,证明了其在临床管理和治疗中作为新型诊断或预后分子标记物的潜在应用。然而,lncRNA在神经胶质瘤的发展和恶性进展中的功能意义仍然不清楚,需要进一步探讨。我们首先使用基因芯片探针重新定位方法从基因表达综合数据库中获得了一大批神经胶质瘤患者的全基因组lncRNA表达谱,并研究了神经胶质瘤在肿瘤发生和恶性进展过程中的lncRNA表达模式。通过使用差异表达分析,我们在训练数据集中发现了大量与神经胶质瘤的发生和恶性进展相关的lncRNA,并在测试数据集中显示了其鲁棒性。随后,我们确定了一种新型的4-lncRNA标记,该标记与GBM患者的预后密切相关。该签名的预后价值在80位患者的测试集中得到了验证。功能分析表明,与GBM患者生存相关的四种lncRNA可能参与了与癌症相关的生物学过程和途径,它们的失调可能导致GBM的肿瘤发生和发展。这些新颖的lncRNA生物标记物将增进我们对神经胶质瘤发展和进程中分子机制的了解,并为神经胶质瘤提供新颖的诊断或预后标记物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号